Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANDORA
2023-505380-36-00Phase 3Withdrawn
- Sponsor
- Gustave Roussy
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cannabidiol in breast cancer and aromatase inhibitor-induced arthralgia (AIA) (2 arms), sponsored by Gustave Roussy. Primary endpoint: Efficacy of CBD on AI-associated joint pain. Planned start Jan 2024; status: withdrawn.
02
Drugs
cannabidiol
03
Conditions
breast canceraromatase inhibitor-induced arthralgia (AIA)
Beyond the preview
Go deeper on 2023-505380-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505380-36-00.